Clinical application of NKT cell biology in type i (autoimmune) diabetes mellitus

Immunology and Cell Biology

Volumn 87, Issue 4, 2009, Pages 315-323

  Fletcher, Marie T ^a   Baxter, Alan G ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b JAMES COOK UNIVERSITY   (Australia)

Author keywords

Autoimmunity; Immunoregulation; Mouse models; Tolerance

Indexed keywords

CD1D ANTIGEN;

ANTIGEN PRESENTING CELL; AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CYTOKINE PRODUCTION; GENE CONTROL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; NONHUMAN; NONOBESE DIABETIC MOUSE; REVIEW; TH17 CELL;

ANIMALS; CYTOKINES; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; HUMANS; MICE; MICE, INBRED NOD; NATURAL KILLER T-CELLS; T-LYMPHOCYTE SUBSETS;

MUS;

EID: 67349255227     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2009.5     Document Type: Review

References (119)

1. Alberti K, Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diab Med 1998; 15: 539-553.
2. Baxter A, Cooke A. The genetics of the NOD mouse. Diab Met Rev 1995; 11: 315-335.
3. Anderson M, Bluestone J. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005; 23:447-485.
4. Hutton J, Eisenbarth G. A pancreatic {beta}-cell-specific homolog of glucose-6- phosphatase emerges as a major target of cell-mediated autoimmunity in diabetes. Proc Natl Acad Sci USA 2003; 100: 8626-8628.
5. Wong F, Karttunen J, Dumont C, Wen L, Visintin I, Pilip I et al. Identification of an MHC class I-restricted autoantigen in type diabetes by screening an organ-specific cDNA library. Nat Med1999; 5: 1026-1031.
6. Dotta F, Gianani R, Previti M, Lenti L, Dionisi S, D'Erme M et al. Autoimmunity to the GM2-islet ganglioside before and at the onset of type I diabetes. Diabetes 1996; 45: 1193-1196.
7. Wegmann D, Norbury-Glaser M, Daniel D. Insulin-specific T cells are a predominant component of islet infiltrates in pre-diabetic NOD mice. Eur J Immunol 1994; 24: 1853-1857.
8. MaierL, WickerL. Geneticsusceptibilitytotypediabetes. Curr OpinImmunol 2005; 17: 601-608.
9. Hattori M, Buss J, Jackson R, Glimcher L, Dorf M, Minami M et al. TheNOD mouse: recessive diabetogenic gene in the major histocompatibility complex. Science 1986; 231: 733-735.
10. Todd J, Bell J, McDevitt H. HLA-DQβ gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987; 329: 599-604.
11. Acha-Orbea H, McDevitt H. The first external domain of the non-obese diabetic mouse class II I-Ab chain is unique. Proc Natl Acad Sci USA 1987; 84: 2435-2439.
12. Pop S, Wong C, Culton D, Clarke S, Tisch R. Single cell analysis shows decreasing FoxPand TGFbetacoexpressing CD4+CD25+ regulatory T cells during autoimmune diabetes. J Exp Med 2005; 201: 1333-1346.
13. Baxter AG, Kinder SJ, Hammond KJ, Scollay R, Godfrey DI. Association between alphabetaTCR+CD4-CD8- T-cell deficiency and IDDM in NOD/Lt mice. Diabetes 1997; 46:572-582.
14. Godfrey DI, Kinder SJ, Silvera P, Baxter AG. Flow cytometric study of T cell development in NOD mice reveals a deficiency in alphabetaTCR+CDR-CD8- thymo- cytes. J Autoimmun 1997; 10: 279-285.
15. Schultz L, Schweitzer P, Christianson S, Gott B, Schweitzer I, Tennent B et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995; 1554:180-191.
16. Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J ClinInvest 2004; 114: 1379-1388.
17. Dellabona P, Padovan E, Casorati M, Brockhaus M, Lanzavecchia A. An invariant Va24-JaQ/VbT cell receptor is expressed in all individuals by clonally expanded CDT cells. J Exp Med 1994; 180: 1171-1176.
18. Lantz O, Bendelac A. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in miceand humans. J Exp Med 1994; 180: 1097-1106.
19. Porcelli S, Yockey C, Brenner M, Balk S. Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- alpha/beta T cells demonstrates preferential use of several Vbeta genes and an invariant TCR alpha chain. J Exp Med 1993; 178:1-16.
20. Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol 2002; 2:557-568.
21. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today 2000; 21: 573-583.
22. Michel ML, Keller AC, Paget C, Fujio M, Trottein F, Savage PB et al. Identification of an IL-17-producingNK1.1(neg)iNKTcell population involvedin airwayneutrophilia. J Exp Med 2007; 204: 995-1001.
23. Pichavant M, Goya S, Meyer EH, Johnston RA, Kim HY, Matangkasombut P et al. Ozone exposure in a mouse model induces airway hyperreactivity that requires the presenceofnatural killer T cells and IL-17. J Exp Med 2008; 205:385-393.
24. Rachitskaya A, Hansen A, Horai R, Li Z, Villasmil R, Luger D et al. Cutting edge: NKT cellsconstitutivelyexpressIL-receptorand RORgammatandrapidlyproduce IL-upon receptor ligation in an IL-6-independent fashion. J Immunol 2008; 180: 5167-5171.
25. Coquet J, Chakravarti S, Kyparissoudis K, McNab F, Pitt L, McKenzie B et al. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc Natl Acad Sci USA 2008; 105: 11287-11292.
26. Gombert JM, Herbelin A, Tancrede-Bohin E, Dy M, Carnaud C, Bach JF. Early quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse. Eur J Immunol 1996; 26: 2989-2998.
27. Wagner MJ, Hussain S, Mehan M, Verdi JM, Delovitch TL. A defect in lineage fate decision during fet al thymic invariant NKT cell development may regulate susceptibility to type diabetes. J Immunol 2005; 174: 6764-6771.
28. Falcone M, Yeung B, Tucker L, Rodriguez E, Sarvetnick N. Adefectin interleukin 12- induced activation and interferon gamma secretion of peripheral natural killer T cells in nonobese diabetic mice suggests new pathogenic mechanisms for insulin-depen-dentdiabetes mellitus. J Exp Med 1999; 190:963-972.
29. Hammond KJL, Poulton LD, Palmisano LJ, Silveira PA, Godfrey DI, Baxter AG. Alpha/Beta-T cell receptor (TCR)(+)Cd4(-)Cd8(-) (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)- and/or IL-10. JExp Med 1998; 187: 1047-1056.
30. Poulton LD, Smyth MJ, Hawke CG, Silveira P, Shepherd D, Naidenko OV et al. Cytometric and functional analyses of NK and NKT cell deficiencies in NOD mice. Int Immunol 2001; 13: 887-896.
31. Lehuen A, Lantz O, Beaudoin L, LalouxV, Carnaud C, Bendelac A et al. Overexpression of natural killer T cells protects V-alpha-14-J-alpha-2transgenic nonobese diabetic mice against diabetes. J Exp Med 1998; 188: 1831-1839.
32. Beaudoin L, Laloux V, Novak J, Lucas B, Lehuen A. NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic beta cells. Immunity 2002; 17: 725-736.
33. Novak J, Beaudoin L, Griseri T, Lehuen A. Inhibition of T cell differentiation into effectors by NKT cells requires cell contacts. J Immunol 2005; 174: 1954-1961.
34. Novak J, Beaudoin L, Park S, Griseri T, Teyton L, Bendelac A et al. Prevention of type diabetes by invariant NKT cells is independent of peripheral CD1d expression. J Immunol 2007; 178: 1332-1340.
35. Naumov YN, Bahjat KS, Gausling R, Abraham R, Exley MA, Koezuka Y et al. Activation ofCD1d-restricted T cells protects NOD micefrom developing diabetes byregulating dendritic cell subsets. Proc Natl Acad Sci USA 2001; 98: 13838-13843.
36. Hong S, Wilson MT, Serizawa I, Wu L, Singh N, Naidenko OV et al. The natural killer T- cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001; 7: 1052-1056.
37. Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, Naidenko OV et al. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type diabetes. Nat Med 2001; 7: 1057-1062.
38. Chen YG, Choisy-Rossi CM, Holl TM, Chapman HD, Besra GS, Porcelli SA et al. Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes. J Immunol 2005; 174: 1196-1204.
39. Mizuno M, Masumura M, Tomi C, Chiba A, Oki S, Yamamura T et al. Synthetic glycolipid OCH prevents insulitis and diabetes in NOD mice. J Autoimmun 2004; 23: 293-300.
40. Forestier C, Takaki T, Molano A, Im JS, Baine I, Jerud ES et al. Improved outcomes in NOD mice treated with a novel Thcytokine-biasing NKT cell activator. J Immunol 2007; 178: 1415-1425.
41. Wang B, Geng YB, Wang CR. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J Exp Med 2001; 194: 313-319.
42. Shi F, Flodstrom M, Balasa B, Kim SH, Van Gunst K, Strominger JL et al. Germ line deletion of the CDlocus exacerbates diabetes in the NOD mouse. Proc Natl Acad Sci USA 2001; 98: 6777-6782.
43. Falcone M, Facciotti F, Ghidoli N, Monti P, Olivieri S, Zaccagnino L et al. Up-regulation of CD1d expression restores the immunoregulatory function of NKT cells and prevents autoimmune diabetes in nonobese diabetic mice. J Immunol 2004; 172: 5908-5916.
44. Cain JA, Smith JA, Ondr JK, Wang B, Katz JD. NKT cells and IFN-{gamma} establish the regulatory environment for the control of diabetogenic T cells in the nonobese diabetic mouse. J Immunol 2006; 176: 1645-1654.
45. Jordan MA, Fletcher JM, Pellicci D, Baxter AG. Slamf1, the NKT cell control gene Nkt1. J Immunol 2007; 178: 1618-1627.
46. Rocha-Campos AC, Melki R, Zhu R, Deruytter N, Damotte D, Dy M et al. Genetic and functional analysis of the Nktlocus using congenic NOD mice: improved V{alpha}14- NKT cell performance but failure to protect against type diabetes. Diabetes 2006; 55: 1163-1170.
47. Fletcher J, Jordan M, Snelgrove S, Slattery R, Dufour F, Kyparissoudis K et al. Congenic analysis of the NKT cell control gene Nktimplicates the peroxisomal protein Pxmp4. J Immunol 2008; 181: 3400-3412.
48. Chen Y, Driver J, Silveira P, Serreze D. Subcongenic analysis of genetic basis for impaired development of invariant NKT cells in NOD mice. Immunogenetics 2007; 59: 705-712.
49. Matsuda JL, Gapin L, BaronJL, Sidobre S, Stetson DB, Mohrs M et al. MouseValpha 14i natural killer T cells are resistant to cytokine polarization in vivo. Proc Natl Acad Sci USA 2003; 100: 8395-8400.
50. Rapoport M, Jaramillo A, Zipris D, Lazarus A, Serreze D, Leiter E et al. Interleukin reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. JExp Med 1993; 178:87-99.
51. Pennline K, Roque-Gaffney E, Monahan M. Recombinant human IL-prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 1994; 71: 169-175.
52. Onoe K, Yanagawa Y, Minami K, lijima N, Iwabuchi K. Thor Thbalance regulated by interaction between dendritic cells and NKT cells. Immunol Res 2007; 38: 319-332.
53. Mi QS, Ly D, Zucker P, McGarry M, Delovitch TL. Interleukin-but not interleukin-protects against spontaneous and recurrent type diabetes by activated CD1d- restricted invariant natural killer T-cells. Diabetes 2004; 53: 1303-1310.
54. Hultgren B, Huang X, Dybdal N, Stewart T. Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice. Diabetes 1996; 45:812.
55. Serreze D, Post C, Chapman H, Johnson E, Lu B, Rothman P. Interferon-gamma receptor signalling is dispensable in the development of autoimmune type diabetes in NOD mice. Diabetes 2000; 49: 2007.
56. Shortman K, Liu Y. Mouse and human dendritic cell subtypes. Nat Rev immunol 2002; 2: 151-161.
57. Vincent M, Leslie DS, Gumperz JE, Xiong X, Grant EP, Brenner MB. CD1-dependent dendritic cell instruction. Nat Immunol 2002; 3: 1163-1168.
58. Fujii S, Shimizu K, Hemmi H, Fukui M, Bonito AJ, Chen G et al. Glycolipid alpha-C- galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc Natl Acad Sci USA2006; 103:11252-11257.
59. Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol 2003; 4:1230-1237.
60. BoudalyS, Morin J, Berthier R, Marche P, Boitard C. Altered dendritic cells (DC) might be responsible for regulatory Tcell imbalance and autoimmunityin nonobese diabetic (NOD) mice. Eur Cytokine Netw 2002; 13:29-37.
61. Dahlen E, Hedlund G, Dawe K. Low CDexpression in the nonobese diabetic mouse results in the impairment of both T cell activation and CTLA-up-regulation. J Immunol 2000; 164: 2444-2456.
62. Albert M, Jegathesan M, Darnell R. Dendritic cell maturation is required for the cross- tolerization of CD8+T cells. Nat Immunol 2001; 2: 1010-1017.
63. Feili-Hariri M, Dong X, Alber SM, Watkins SC, Salter RD, Morel PA. Immunotherapy of NOD mice with bone marrow-derived dendritic cells. Diabetes 1999; 48: 2300-2308.
64. Kojo S, Seino K, Harada M, Watarai H, Wakao H, Uchida T et al. Induction of regulatory properties in dendritic cells by V{alpha}NKT cells. J Immunol 2005; 175: 3648-3655.
65. LiuR,LaCavaA,BaiXF,JeeY,PriceM,CampagnoloDIet al. Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. J Immunol 2005; 175: 7898-7904.
66. Roelofs-Haarhuis K, Wu X, Gleichmann E. Oral tolerance to nickel requires CD4+ invariant NKT cells for the infectious spread of tolerance and the induction of specific regulatory T cells. J Immunol 2004; 173: 1043-1050.
67. Jiang S, Game DS, Davies D, Lombardi G, Lechler RI. Activated CD1d-restricted natural killer T cells secrete IL-2: innate help for CD4(+)CD25(+) regulatory T cells? Eur J Immunol 2005; 35: 1193-1200.
68. LyD, Mi QS, Hussain S, Delovitch TL. Protection from typediabetes byinvariant NK T cells requires the activity of CD4+CD25+ regulatory T cells. J Immunol 2006; 177:3695-3704.
69. Bettelli E, Korn T, Kuchroo VK. Th17: the third member of the effector T cell trilogy. Curr Opin Immunol 2007; 19: 652-657.
70. Gran B, Zhang G, Yu S, Li J, Chen X, Ventura E et al. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the ILsystem in the induction of central nervous system autoimmune demyelination. J Immunol 2002; 169: 7104-7110.
71. Becher B, Durell B, Noelle R. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J ClinInvest 2002; 110: 493-497.
72. Zhang G, Gran B, Yu S, Li J, Siglienti I, Chen X et al. Induction of experimental autoimmune encephalomyelitis in IL-receptor-beta 2-deficient mice: IL-responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system. J Immunol 2003; 170: 2153-2160.
73. Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M et al. Reciprocal developmental pathways for thegeneration of pathogenic effector THand regulatoryT cells. Nature 2006; 441: 235-238.
74. Cua D, Sherlock J, Chen Y, MurphyC, Joyce B, Seymour B et al. Interleukin-rather than interleukin-is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; : 744-748.
75. Langrish C, Chen Y, Blumenschein W, McClanahan T, Kastelein R, Cua D. IL-drives a pathogenic T cell population that induces autoimmune inflammation. JExp Med 2005; 201: 233-240.
76. Hirota K, Hashimoto M, Yoshitomi H, Tanaka S, Nomura T, Yamaguchi T et al. Tcell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med 2007; 204:41-47.
77. Jain R, Tartar DM, Gregg RK, Divekar RD, Bell JJ, Lee HH et al. Innocuous IFNgamma induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-production. J Exp Med 2008; 205: 207-218.
78. Srinivasan S, Bolick DT, LukashevD, Lappas C, SitkovskyM, Lynch KR. Sphingosine- 1-phosphate reduces CD4+ T-cell activation in type diabetes through regulation of hypoxia-inducible factor short isoform I.and CD69. Diabetes 2008; 57: 484-493.
79. Coquet JM, Kyparissoudis K, Pellicci DG, Besra G, Berzins SP, Smyth MJ et al. IL-is produced by NKT cells and modulates NKTcell activation and cytokine production. J Immunol 2007; 178: 2827-2834.
80. Zhou L, IvanovI, Spolski R, Min R, ShenderovK, Egawa Tet al. IL-programs T(H)-cell differentiation by promoting sequential engagement of the IL-and IL-23pathways. Nat Immunol 2007; 8:967-974.
81. Nurieva R, Yang X, Martinez G, Zhang Y, Panopoulos A, Ma L et al. Essential autocrine regulation by IL-in the generation of inflammatory T cells. Nature 2007; 448: 480-483.
82. Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom T et al. IL-initiates an alternative pathway to induce proinflammatory T(H)cells. Nature 2007; 448: 484-487.
83. Rachitskaya AV, Hansen AM, Horai R, Li Z, Villasmil R, Luger D et al. Cutting edge: NKT cells constitutively express IL-receptor and RORgammat and rapidly produce IL-upon receptor ligation in an IL-6-independent fashion. J Immunol 2008; 180: 5167-5171.
84. Hammond KJL, Pellicci DG, Poulton LD, Naidenko OV, Scalzo AA, Baxter AG et al. CD1d-restricted NKT cells: an interstrain comparison. J Immunol 2001; 167: 1164-1173.
85. Wilson SB, Kent SC, Patton KT, Orban T, Jackson RA, Exley M et al. Extreme THbias of invariant V-alpha-24J-alpha-Q T cells in type diabetes. Nature 1998; 391:177-181.
86. Wilson S, Kent S, Horton H, Hill A, Bollyky P, Hafler D et al. Multiple differences in gene expression in regulatory Valpha24Jalpha QT cells from identical twins discordant for type diabetes. Proc Natl Acad Sci USA 2000; 97: 7411-7416.
87. Kukreja A, Cost G, Marker J, Zhang CH, Sun Z, Lin-Su K et al. Multiple immuno-regulatory defects in type-diabetes. J Clin Invest 2002; 109:131-140.
88. Lee PT, Putnam A, Benlagha K, Teyton L, Gottlieb PA, Bendelac A. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 2002; 110:793-800.
89. Oikawa Y, Shimada A, Yamada S, Motohashi Y, Nakagawa Y, Irie J et al. High frequency of valpha24(+) vbeta11(+) T-cells observed in type diabetes. Diabetes Care 2002; 25: 1818-1823.
90. Poulton L, Baxter A. Clinical application of NKT cell assays to the prediction of type diabetes. Diab Met Res Rev 2001; 17: 429-435.
91. Tsutsumi Y, Jie X, Ihara K, Nomura S, Kanemitsu H, Takada H et al. Phenotypic and genetic analyses of T-cell-mediated immunoregulation in patients with type diabetes. Diab Med 2006; 23: 1145-1150.
92. Kis J, Engelmann P, Klara F, Richman G, Eck S, Lolley J et al. Reduced CD4+ subset and Thbias of the human iNKT cells in type diabetes mellitus. J Leukoc Biol 2006; 81: 654-662.
93. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004; 4: 231-237.
94. Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 2002; 195: 625-636.
95. Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human V alpha-natural killer T cells. J Exp Med 2002; 195:637-641.
96. Oikawa Y, Shimada A, Yamada S, Motohashi Y, Nakagawa Y, Irie J et al. NKT cell frequency in Japanese type diabetes. Ann NY Acad Sci 2003; 1005: 230-232.
97. Berzins SP, Kyparissoudis K, Pellicci DG, Hammond KJ, Sidobre S, Baxter A et al. Systemic NKT cell deficiency in NOD mice is not detected in peripheral blood: implications for human studies. Immunol Cell Biol 2004; 82:247-252.
98. Kent SC, Chen Y, Clemmings SM, Viglietta V, Kenyon NS, Ricordi C et al. Lossof IL-secretion from human type 1a diabetic pancreatic draining lymph node NKT cells. J Immunol 2005; 175: 4458-4464.
99. van der Vliet HJ, Molling JW, Nishi N, Masterson AJ, Kolgen W, Porcelli SA et al. Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells. Cancer Res 2003; 63: 4101-4106.
100. Esteban LM, Tsoutsman T, Jordan MA, Roach D, Poulton LD, Brooks A et al. Genetic control of NKT cell numbers maps to major diabetes and lupus loci. J Immunol 2003; 1: 2873-2878.
101. Jordan M, Silveira P, Shepherd D, Chu C, Kinder S, Chen J et al. Linkage analysis of systemic lupus erythematosus induced in diabetes-prone nonobese diabetic mice by Mycobacterium bovis. J Immunol 2000; 165: 1673-1684.
102. Hamilton-Williams E, Serreze D, CHarlton B, Johnson E, Marron M, Mullbacher A et al. Transgenic rescue implicates B2-microglobulin as a diabetes susceptibility gene in nonobese diabetic (NOD) mice. Proc Natl Acad Sci USA 2001; 98: 11533-11538.
103. Pasquier B, Yin L, Fondaneche MC, Relouzat F, Bloch-Queyrat C, Lambert N et al. Defective NKT cell development in mice and humans lacking the adapter SAP, the X- linked lymphoproliferative syndrome gene product. J Exp Med 2005; 201:695-701.
104. Nichols KE, Hom J, Gong SY, Ganguly A, Ma CS, Cannons JL et al. Regulation of NKT cell development by SAP, the protein defective in XLP. Nat Med 2005; 11:340-345.
105. Chung B, Aoukaty A, Dutz J, Terhorst C, Tan R. Cutting edge: signaling lymphocytic activation molecule-associated protein controls NKT cell functions. J Immunol 2005; 174: 3153-3157.
106. Eberl G, Lowin-Kropf B, MacDonald HR. Cutting edge: NKT cell development is selectively impaired in Fyn-deficient mice. J Immunol 1999; 163: 4091-4094.
107. Gadue P, Morton N, Stein PL. The Src family tyrosine kinase Fyn regulates natural killer T cell development. J Exp Med 1999; 190: 1189-1196.
108. Griewank K, Borowski C, Rietdijk S, Wang N, Julien A, Wei DG et al. Homotypic interactions mediated by Slamfand Slamfreceptors control NKT cell lineage development. Immunity 2007; 27: 751-762.
109. Baev D, Caielli S, Ronchi F, Coccia M, Facciotto F, Nichols K et al. Impaired SLAM- SLAM homotypic interaction between invariant NKT cells and dendritic cells affects differentiation of IL-4/IL-10-secreting NKTcells in nonobese diabetic mice. J Immunol 2008; 181:869-877.
110. Serreze D, Bridgett M, Chapman H, Chen E, Richard S, Leiter E. Subcongenic analysis of the Iddlocus in NOD/Lt mice: evidence for several susceptibility genes including a possible diabetogenic role for beta 2-microglobulin. J Immunol 1998; 160: 1472-1478.
111. Titorenko V, Rachiubinski R. The peroxisome: orchestrating important developmental decisions from inside the cell. J Cell Biol 2004; 164: 641-645.
112. Sacksteder K, Jones J, South S, Li X, Liu Y, Gould S. PEXbinds multiple peroxisomal membrane proteins, is predominantly cytoplasmic, and is required for peroxisome membrane synthesis. J Cell Biol 2000; 148: 931-944.
113. Concannon P, Gogolin-Ewens K, Hinds D, Wapelhorst B, Morrison V, Stirling B et al. A second-generation screen of the human genome for susceptibility to insulin-dependent diabetes mellitus. Nat Genet 1998; 19: 292-296.
114. Ewens K, Johnson L, Wapelhorst B, O'Brien K, Gutin S, Morrison V et al. Linkage and association with type diabetes on chromosome 1q42. Diabetes 2002; 51: 3318-3325.
115. Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, IdeK et al. Therapeutic activation of V{alpha}24+V{beta}11+NKT cellsin human subjectsresultsin highlycoordinated secondaryactivation of acquired and innate immunity. Blood 2004; 103: 383-389.
116. GiacconeG, PuntCJA, Ando Y, RuijterR, Nishi N, PetersM et al. AphaseI studyof the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002; 8: 3702-3709.
117. IshikawaA, Motohashi S, IshikawaE, FuchidaH, HigashinoK, Otsuji M et al. Aphase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lungcancer. Clin Cancer Res 2005; 11:1910-1917.
118. RogersPR, MatsumotoA, NaidenkoO, KronenbergM, MikayamaT, KatoS. Expansion of human Valpha24(+)NKT cells byrepeated stimulation with KRN7000. J Immunol Methods 2004; 285:197-214.
119. van der Vliet HJJ, Nishi N, Koezuka Y, von Blomberg BME, van den Eertwegh AJM, Porcelli SA et al. Potent expansion of human natural killer T cells using alpha- galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-and IL-15. J Immunol Methods 2001; 247:61-72.